| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | HELIXOMER, INC. | 1428 CHANTERELLE LANE | HILLSBOROUGH, | NC | 27278-9661 | | USA | R44HL167436 | Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures | 000 | 2 | NIH | 10/28/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,058,454 ) |
| | 2024 | 2024 | HELIXOMER, INC. | 1428 CHANTERELLE LANE | HILLSBOROUGH, | NC | 27278-9661 | | USA | R44HL167436 | Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures | 000 | 2 | NIH | 8/28/2024 | $1,058,454 |
|
| Issue Date FY: 2023 ( Subtotal = $983,573 ) |
| | 2023 | 2023 | HELIXOMER, INC. | 1428 CHANTERELLE LANE | HILLSBOROUGH, | NC | 27278-9661 | | USA | R44HL167436 | Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures | 000 | 1 | NIH | 8/30/2023 | $983,573 |
|
|
